Participated · Seed · Mar 2024

PayShepherd provides a cloud-based contractor management platform purpose-built for heavy industrial sites, automating contract compliance and enabling real-time cost reporting, accountability, and risk management. The company centralizes contractor data to replace paper-heavy administrative processes and to surface efficiencies across procurement, maintenance, and capital projects. Since launching in 2018 it has managed billions in contractor cost submissions and has entered energy and mining markets. PayShepherd plans to expand across Canada and the United States and to enhance its platform with new capabilities, including deeper use of artificial intelligence. Its product roadmap emphasizes building a comprehensive, frictionless system of record between contractors and clients. Financially, PayShepherd has grown since its 2022 seed and has now raised C$12.1 million in equity financing to date. PayShepherd provides a billing management and contract-assurance platform that automates billing review, validates contract and collective agreement logic, and identifies invoice discrepancies across labour, equipment, materials and third‑party expenses. The platform runs historical audits, works with multiple contractors simultaneously, and has benchmarked savings in excess of US$1M yearly per major facility. PayShepherd’s validation engine serves as a digital source of truth to reduce overspending, speed payments, and improve facility–contractor relationships. The company says its software increases visibility and accountability, enabling closer alignment to strategic goals and faster, more accurate payments. PayShepherd was founded in 2018 and is headquartered in Calgary, Canada, with offices in Vancouver and Charlotte, North Carolina. The new funding will support expanded product and engineering capabilities, stronger operations across Canada and the U.S., new verticals, and additional ecosystem integrations. PayShepherd is a Calgary-based fintech that provides contractor billing software to help large industrial facilities manage contractor billing. Its platform captures high-volume contracts and timesheets, detects overbilling, and makes contract history transparent for facility owners and contractors. Founded in 2018 as Project Recapture, the company’s current customers include multinational conglomerates with dozens of facilities across Canada, the US and Europe. PayShepherd plans to use the $700,000 CAD pre-seed to boost sales and business development, bolster its product, and add customers across Canada and the United States. The startup has grown headcount from three to eight employees, is hiring two more software engineers, and aims to expand across North America and add at least 20 more facility clients over the next 18 months. Longer-term plans include offering invoice financing for contractors and delivering aggregate spending-data insights to the heavy-industry market.

Participated · Seed · Sep 2021

PhenoTips provides an interoperable software platform for medical genetics that enables deep phenotyping, family history recording, and genomic analysis. Its technology is used by genetic care providers in four countries, across four NHS Trusts and two Canadian provincial health systems, currently serving over 200,000 patients. The company began as an academic research project at The Hospital for Sick Children and the University of Toronto and was founded in 2014. PhenoTips operates a Canada-based team of twelve people and plans to double headcount while expanding its cloud-based product offerings. Leadership emphasizes the use of software and AI to integrate genetics into mainstream healthcare, advance diagnostics, and support research. The company positions itself to capitalize on growing genetic testing adoption as sequencing costs fall.

Participated · Seed · Aug 2021

Fluid Biomed is a clinical-stage medical device company based in Calgary, Alberta, developing ReSolv™, the world’s first bioabsorbable polymer-based neurovascular stent for brain aneurysms. The ReSolv™ stent has been validated by years of scientific research and demonstrated functional benefits in a first-in-human clinical study. The technology was developed by co-founders John Wong, M.D. (CEO), and Alim Mitha, M.D. (President and CTO), both academic neurosurgeons at the University of Calgary. The company plans to use recent financing to further validate the ReSolv™ stent and its proprietary delivery system in expanded patient studies and to enable larger clinical trials. Fluid Biomed also intends to broaden its product pipeline with the additional strategic and financial capital. Fluid Biotech is commercializing a hybrid polymer-metal flow-diverting brain stent constructed of bioabsorbable polymer and metal to provide a scaffold that enables better healing and vessel visualization. Led by Dr. John Wong (CEO) and Dr. Alim Mitha (President and CTO), the company aims to cure intracranial aneurysms with this novel device. Fluid closed a $4.7M seed funding round to advance development. The company intends to use the funds to engage contract manufacturers to initiate production, complete regulatory milestones, and plan for first-in-human implantation. In conjunction with the raise, Fluid added two board members with capital and industry experience to support commercialization and regulatory progress. The company is based in Calgary, Alberta, Canada.

Participated · Series A · Sep 2020

Athennian provides cloud software that powers legal, tax and finance teams to digitize, streamline and manage business entities and company structures. Its platform enables clients to manage and automate workflows for ownership, governance, tax, and corporate compliance. Led by CEO Adrian Camara, the company serves over 2,500 users and manages nearly 400,000 business entities on its platform. Over the last 24 months Athennian reports a 500% increase in annual recurring revenue. The company is headquartered in Calgary, Alberta, maintains a second office in Toronto, and has additional team members located across the U.S. It intends to use new funding to continue a proactive approach to scaling the business. Athennian provides a cloud-based legal entity management platform used by legal departments and professional services firms to automate subsidiary and entity management and improve compliance, governance, and transactional workflows. The platform leverages data to generate reports and tax charts, produce required documents (share certificates, minutes, stock and dividend transactions, changes of directors or officers), submit registrations digitally, provide reminders for annual filings, and automate workflows with document assembly, eSignature, and e-filing directly with government registries. Athennian also offers rapid migration from many legacy databases, including Diligent Entities (Blueprint), GEMS, Secretariat, hCue, Effacts, Viewpoint, ALF, CorpLink, EnAct, GlobalAct, and others. Led by CEO Adrian Camara, the company will use new capital to increase the size of its global team, invest in product development, and expand its cloud-based services. The article states the company is based in Calgary, Canada. Athennian has raised CAD$17M in venture capital financing to date. Athennian develops a cloud-based legal entity management software platform used by legal departments and professional services firms to automate subsidiary and entity management. The platform integrates document generation, eSignatures, e-filing, and project management to automate workflows such as entity formation, appointments, transactions, and annual compliance. It offers rapid migration from legacy databases including Diligent Entities (Blueprint), GEMS, Secretariat, hCue, Effacts, Viewpoint, ALF, CorpLink, EnAct, GlobalAct, EnGlobe, FastCompany, Corporate Focus, and more. Led by CEO Adrian Camara and based in Calgary, Canada, the company serves a growing global customer base. Athennian has raised $10M in total — a $2M seed in Q3 2019 and an $8M Series A — and intends to use the proceeds to accelerate product-led growth and scale its cloud infrastructure.

Participated · Series A · Jul 2020

Orpyx builds the Sensory Insole system that integrates multi-modal sensor technology with a dedicated team of specialized nurses to enable continuous remote monitoring of plantar pressure, temperature, activity, and adherence. The system is used to prevent diabetic foot ulcers (DFU) and lower-limb amputations by empowering patients with personalized remote care. Orpyx partners with U.S. health plans and organizations such as the Veterans Health Administration to deploy its solution. The company announced an additional $20 million in growth capital to accelerate its commercial efforts and expand patient access. Orpyx positions itself as a leader in DFU and amputation prevention and emphasizes improving mobility and healthspan for people with diabetes and peripheral neuropathy. The company lists New York and Calgary, Alberta in its announcement and focuses on scaling clinical and payer relationships. Orpyx Medical Technologies develops the Orpyx SI Sensory Insoles, a sensory insole with telemedicine capabilities that delivers real-world plantar pressure feedback and real-time analytics to help prevent diabetic foot and neuropathy-related ulcers. The technology also provides clinical-grade plantar pressure data for researchers in sports medicine, therapeutic applications and footwear design. Led by Dr. Breanne Everett, CEO and co‑inventor, the company plans to use new funding to expand North American commercialization and to broaden and accelerate technology development. Orpyx is based in Calgary, Canada. The company closed a $7.6M Series A round in 2020, bringing total funding since inception to $18.5M.